GLIBA vs LILAK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GLIBA exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and deteriorating operational efficiency. While the company maintains a strong liquidity position with a current ratio of 3.14 and trades at a discount to book value (P/B 0.85), these are offset by negative net profit margins (-29.54%) and stagnant revenue growth. A significant earnings miss of 66% in the most recent reported quarter further underscores the disconnect between current performance and the optimistic single-analyst target price of $68.00.
LILAK exhibits severe fundamental weakness, anchored by a Piotroski F-Score of 2/9, indicating poor financial health. The company is burdened by extreme leverage with a Debt/Equity ratio of 8.32, far exceeding sector averages. While the 1-year price performance is positive, this is disconnected from a negative ROE of -41.72% and stagnant revenue growth of 1.70%. The combination of bearish insider sentiment and a history of massive earnings misses suggests the current valuation is unsustainable.
Compare Another Pair
Related Comparisons
GLIBA vs LILAK: Head-to-Head Comparison
This page compares GCI Liberty, Inc. - Series A GC (GLIBA) and Liberty Latin America Ltd. (LILAK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.